{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Parkinson\u2019s disease (PD)", "REM behavior disorder (RBD)", "melatonin", "sleep disturbances"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37371392", "DateRevised": {"Year": "2023", "Month": "07", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "06", "Day": "06"}], "Language": ["eng"], "ELocationID": ["914", "10.3390/brainsci13060914"], "Journal": {"ISSN": "2076-3425", "JournalIssue": {"Volume": "13", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Jun", "Day": "06"}}, "Title": "Brain sciences", "ISOAbbreviation": "Brain Sci"}, "ArticleTitle": "Parkinson's Disease: A Narrative Review on Potential Molecular Mechanisms of Sleep Disturbances, REM Behavior Disorder, and Melatonin.", "Abstract": {"AbstractText": ["Parkinson's disease (PD) is one of the most common neurodegenerative diseases. There is a wide range of sleep disturbances in patients with PD, such as insomnia and rapid eye movement (REM) sleep behavior disorder (or REM behavior disorder (RBD)). RBD is a sleep disorder in which a patient acts out his/her dreams and includes abnormal behaviors during the REM phase of sleep. On the other hand, melatonin is the principal hormone that is secreted by the pineal gland and significantly modulates the circadian clock and mood state. Furthermore, melatonin has a wide range of regulatory effects and is a safe treatment for sleep disturbances such as RBD in PD. However, the molecular mechanisms of melatonin involved in the treatment or control of RBD are unknown. In this study, we reviewed the pathophysiology of PD and sleep disturbances, including RBD. We also discussed the potential molecular mechanisms of melatonin involved in its therapeutic effect. It was concluded that disruption of crucial neurotransmitter systems that mediate sleep, including norepinephrine, serotonin, dopamine, and GABA, and important neurotransmitter systems that mediate the REM phase, including acetylcholine, serotonin, and norepinephrine, are significantly involved in the induction of sleep disturbances, including RBD in PD. It was also concluded that accumulation of \u03b1-synuclein in sleep-related brain regions can disrupt sleep processes and the circadian rhythm. We suggested that new treatment strategies for sleep disturbances in PD may focus on the modulation of \u03b1-synuclein aggregation or expression."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 3365166571, Iran."}], "LastName": "Samizadeh", "ForeName": "Mohammad-Ali", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran 1417935840, Iran."}], "LastName": "Fallah", "ForeName": "Hamed", "Initials": "H"}, {"Identifier": ["0000-0003-4446-0474"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 3365166571, Iran."}], "LastName": "Toomarisahzabi", "ForeName": "Mohadeseh", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 3365166571, Iran."}], "LastName": "Rezaei", "ForeName": "Fereshteh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 3365166571, Iran."}], "LastName": "Rahimi-Danesh", "ForeName": "Mehrsa", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran 13337159140, Iran."}], "LastName": "Akhondzadeh", "ForeName": "Shahin", "Initials": "S"}, {"Identifier": ["0000-0002-2436-9887"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 3365166571, Iran."}], "LastName": "Vaseghi", "ForeName": "Salar", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Brain Sci", "NlmUniqueID": "101598646", "ISSNLinking": "2076-3425"}, "CoiStatement": "The authors declare that they have no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Kalia L.V., Lang A.E. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912. doi: 10.1016/S0140-6736(14)61393-3.", "ArticleIdList": ["10.1016/S0140-6736(14)61393-3", "25904081"]}, {"Citation": "Zafar S., Yaddanapudi S.S. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2022. Parkinson disease."}, {"Citation": "Rl N. Alzheimer\u2019s disease and Parkinson\u2019s disease. N. Engl. J. Med. 2003;348:1356\u20131364.", "ArticleIdList": ["12672864"]}, {"Citation": "Chen R., Chang S., Su C., Chen T., Yen M., Wu H., Chen Z., Liou H. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology. 2001;57:1679\u20131686. doi: 10.1212/WNL.57.9.1679.", "ArticleIdList": ["10.1212/WNL.57.9.1679", "11706111"]}, {"Citation": "Su D., Su Y., Xu B., Chhetri J.K., Chan P. Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson\u2019s disease: Results from a single-center trial. Medicine. 2023;102:e33161. doi: 10.1097/MD.0000000000033161.", "ArticleIdList": ["10.1097/MD.0000000000033161", "PMC9981374", "36862872"]}, {"Citation": "DeMaagd G., Philip A. Parkinson\u2019s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm. Ther. 2015;40:504.", "ArticleIdList": ["PMC4517533", "26236139"]}, {"Citation": "Jankovic J., Tintner R. Dystonia and parkinsonism. Park. Relat. Disord. 2001;8:109\u2013121. doi: 10.1016/S1353-8020(01)00025-6.", "ArticleIdList": ["10.1016/S1353-8020(01)00025-6", "11489676"]}, {"Citation": "Kataoka H., Obayashi K., Tai Y., Sugie K., Saeki K. Increased depressive symptoms in Parkinson\u2019s disease during the COVID-19 pandemic: Preliminary findings from longitudinal analysis of the PHASE study. Clin. Park. Relat. Disord. 2023;8:100194. doi: 10.1016/j.prdoa.2023.100194.", "ArticleIdList": ["10.1016/j.prdoa.2023.100194", "PMC10030263", "36974118"]}, {"Citation": "Pisani S., Gunasekera B., Lu Y., Vignando M., Aarsland D., Chaudhuri K.R., Ballard C., Lee J.-Y., Kim Y.K., Velayudhan L. Grey matter volume loss in Parkinson\u2019s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis. Neurosci. Biobehav. Rev. 2023;147:105081. doi: 10.1016/j.neubiorev.2023.105081.", "ArticleIdList": ["10.1016/j.neubiorev.2023.105081", "36775084"]}, {"Citation": "Lacy B., Piotrowski H.J., Dewey R.B., Jr., Husain M.M. Severity of depressive and motor symptoms impacts quality of life in Parkinson\u2019s disease patients at an academic movement clinic: A cross-sectional study. Clin. Park. Relat. Disord. 2023;8:100180. doi: 10.1016/j.prdoa.2022.100180.", "ArticleIdList": ["10.1016/j.prdoa.2022.100180", "PMC9795528", "36590453"]}, {"Citation": "Reichmann H. Clinical criteria for the diagnosis of Parkinson\u2019s disease. Neurodegener. Dis. 2010;7:284\u2013290. doi: 10.1159/000314478.", "ArticleIdList": ["10.1159/000314478", "20616563"]}, {"Citation": "Munhoz R.P., Werneck L.C., Teive H.A. The differential diagnoses of parkinsonism: Findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin. Neurol. Neurosurg. 2010;112:431\u2013435. doi: 10.1016/j.clineuro.2010.03.003.", "ArticleIdList": ["10.1016/j.clineuro.2010.03.003", "20347518"]}, {"Citation": "Zuzu\u00e1rregui J.R.P., During E.H. Sleep issues in Parkinson\u2019s disease and their management. Neurotherapeutics. 2020;17:1480\u20131494. doi: 10.1007/s13311-020-00938-y.", "ArticleIdList": ["10.1007/s13311-020-00938-y", "PMC7851262", "33029723"]}, {"Citation": "Muntean M.-L., Benes H., Sixel-D\u00f6ring F., Chaudhuri K.R., Suzuki K., Hirata K., Zimmermann J., Trenkwalder C. Clinically relevant cut-off values for the Parkinson\u2019s Disease Sleep Scale-2 (PDSS-2): A validation study. Sleep. Med. 2016;24:87\u201392. doi: 10.1016/j.sleep.2016.06.026.", "ArticleIdList": ["10.1016/j.sleep.2016.06.026", "27810191"]}, {"Citation": "Zhu K., van Hilten J.J., Marinus J. The course of insomnia in Parkinson\u2019s disease. Park. Relat. Disord. 2016;33:51\u201357. doi: 10.1016/j.parkreldis.2016.09.010.", "ArticleIdList": ["10.1016/j.parkreldis.2016.09.010", "27639814"]}, {"Citation": "Tan S., Zhou C., Wen J., Duanmu X., Guo T., Wu H., Wu J., Cao Z., Liu X., Chen J. Presence but not the timing of onset of REM sleep behavior disorder distinguishes evolution patterns in Parkinson\u2019s disease. Neurobiol. Dis. 2023;180:106084. doi: 10.1016/j.nbd.2023.106084.", "ArticleIdList": ["10.1016/j.nbd.2023.106084", "36931531"]}, {"Citation": "Nagy A., Leschziner G., Eriksson S., Lees A., Noyce A., Schrag A. Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson\u2019s disease. Park. Relat. Disord. 2023;109:105312. doi: 10.1016/j.parkreldis.2023.105312.", "ArticleIdList": ["10.1016/j.parkreldis.2023.105312", "36827949"]}, {"Citation": "Dauvilliers Y., Schenck C.H., Postuma R.B., Iranzo A., Luppi P.-H., Plazzi G., Montplaisir J., Boeve B. REM sleep behaviour disorder. Nat. Rev. Dis. Prim. 2018;4:19. doi: 10.1038/s41572-018-0016-5.", "ArticleIdList": ["10.1038/s41572-018-0016-5", "30166532"]}, {"Citation": "Burre J., Sharma M., Sudhof T.C. Cell Biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb. Perspect. Med. 2018;8:a024091. doi: 10.1101/cshperspect.a024091.", "ArticleIdList": ["10.1101/cshperspect.a024091", "PMC5519445", "28108534"]}, {"Citation": "Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging. 2003;24:197\u2013211. doi: 10.1016/S0197-4580(02)00065-9.", "ArticleIdList": ["10.1016/S0197-4580(02)00065-9", "12498954"]}, {"Citation": "Horsager J., Knudsen K., Sommerauer M. Clinical and imaging evidence of brain-first and body-first Parkinson\u2019s disease. Neurobiol. Dis. 2022;164:105626. doi: 10.1016/j.nbd.2022.105626.", "ArticleIdList": ["10.1016/j.nbd.2022.105626", "35031485"]}, {"Citation": "Hawkes C.H., Del Tredici K., Braak H. Parkinson\u2019s disease: A dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 2007;33:599\u2013614. doi: 10.1111/j.1365-2990.2007.00874.x.", "ArticleIdList": ["10.1111/j.1365-2990.2007.00874.x", "PMC7194308", "17961138"]}, {"Citation": "Chen Z., Li G., Liu J. Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol. Dis. 2020;134:104700. doi: 10.1016/j.nbd.2019.104700.", "ArticleIdList": ["10.1016/j.nbd.2019.104700", "31809788"]}, {"Citation": "Boeve B.F., Silber M.H., Saper C.B., Ferman T.J., Dickson D.W., Parisi J.E., Benarroch E.E., Ahlskog J.E., Smith G.E., Caselli R.C., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130:2770\u20132788. doi: 10.1093/brain/awm056.", "ArticleIdList": ["10.1093/brain/awm056", "17412731"]}, {"Citation": "Kalaitzakis M.E., Graeber M.B., Gentleman S.M., Pearce R.K. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson\u2019s disease: A critical analysis of alpha-synuclein staging. Neuropathol. Appl. Neurobiol. 2008;34:284\u2013295. doi: 10.1111/j.1365-2990.2007.00923.x.", "ArticleIdList": ["10.1111/j.1365-2990.2007.00923.x", "18053026"]}, {"Citation": "Parkkinen L., Pirttila T., Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399\u2013407. doi: 10.1007/s00401-008-0346-6.", "ArticleIdList": ["10.1007/s00401-008-0346-6", "PMC2270355", "18297293"]}, {"Citation": "Zhang J., Xu C.Y., Liu J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson\u2019s disease. BMC Neurol. 2017;17:23. doi: 10.1186/s12883-017-0795-4.", "ArticleIdList": ["10.1186/s12883-017-0795-4", "PMC5292147", "28160778"]}, {"Citation": "Sixel-Doring F., Zimmermann J., Wegener A., Mollenhauer B., Trenkwalder C. The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease. Sleep. 2016;39:1737\u20131742. doi: 10.5665/sleep.6102.", "ArticleIdList": ["10.5665/sleep.6102", "PMC4989262", "27306265"]}, {"Citation": "Nagayama H., Hamamoto M., Ueda M., Nagashima J., Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 2005;76:249\u2013251. doi: 10.1136/jnnp.2004.037028.", "ArticleIdList": ["10.1136/jnnp.2004.037028", "PMC1739515", "15654042"]}, {"Citation": "Kashihara K., Imamura T., Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson\u2019s disease. Parkinsonism Relat. Disord. 2010;16:252\u2013255. doi: 10.1016/j.parkreldis.2009.12.010.", "ArticleIdList": ["10.1016/j.parkreldis.2009.12.010", "20097595"]}, {"Citation": "Borghammer P., Van Den Berge N. Brain-First versus Gut-First Parkinson\u2019s Disease: A Hypothesis. J. Parkinson\u2019s Dis. 2019;9:S281\u2013S295. doi: 10.3233/JPD-191721.", "ArticleIdList": ["10.3233/JPD-191721", "PMC6839496", "31498132"]}, {"Citation": "Borghammer P. The alpha-Synuclein Origin and Connectome Model (SOC Model) of Parkinson\u2019s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. J. Parkinson\u2019s Dis. 2021;11:455\u2013474. doi: 10.3233/JPD-202481.", "ArticleIdList": ["10.3233/JPD-202481", "PMC8150555", "33682732"]}, {"Citation": "Dipiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., Posey L.M. Pharmacotherapy: A pathophysiologic approach, ed. Conn. Appleton Lange. 2014;4:141\u2013142."}, {"Citation": "Young C.B., Reddy V., Sonne J. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Neuroanatomy, Basal Ganglia.", "ArticleIdList": ["30725826"]}, {"Citation": "Wolters E., Braak H. Parkinson\u2019s disease: Premotor clinico-pathological correlations. J. Neural Transm. Suppl. 2006;70:309\u2013319. doi: 10.1007/978-3-211-45295-0_47.", "ArticleIdList": ["10.1007/978-3-211-45295-0_47", "17017546"]}, {"Citation": "Postuma R.B., Aarsland D., Barone P., Burn D.J., Hawkes C.H., Oertel W., Ziemssen T. Identifying prodromal Parkinson\u2019s disease: Pre-motor disorders in Parkinson\u2019s disease. Mov. Disord. 2012;27:617\u2013626. doi: 10.1002/mds.24996.", "ArticleIdList": ["10.1002/mds.24996", "22508280"]}, {"Citation": "Siderowf A., Lang A.E. Premotor Parkinson\u2019s disease: Concepts and definitions. Mov. Disord. 2012;27:608\u2013616. doi: 10.1002/mds.24954.", "ArticleIdList": ["10.1002/mds.24954", "PMC3335740", "22508279"]}, {"Citation": "Braak H., Braak E. Pathoanatomy of Parkinson\u2019s disease. J. Neurol. 2000;247((Suppl. 2)):II3\u2013II10. doi: 10.1007/PL00007758.", "ArticleIdList": ["10.1007/PL00007758", "10991663"]}, {"Citation": "Kovari E., Horvath J., Bouras C. Neuropathology of Lewy body disorders. Brain Res. Bull. 2009;80:203\u2013210. doi: 10.1016/j.brainresbull.2009.06.018.", "ArticleIdList": ["10.1016/j.brainresbull.2009.06.018", "19576266"]}, {"Citation": "Chu J., Wagle-Shukla A., Gunraj C., Lang A.E., Chen R. Impaired presynaptic inhibition in the motor cortex in Parkinson disease. Neurology. 2009;72:842\u2013849. doi: 10.1212/01.wnl.0000343881.27524.e8.", "ArticleIdList": ["10.1212/01.wnl.0000343881.27524.e8", "19255412"]}, {"Citation": "Galvan A., Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. Prog. Brain Res. 2007;160:287\u2013312. doi: 10.1016/S0079-6123(06)60017-4.", "ArticleIdList": ["10.1016/S0079-6123(06)60017-4", "17499121"]}, {"Citation": "Bridi J.C., Hirth F. Mechanisms of alpha-Synuclein Induced Synaptopathy in Parkinson\u2019s Disease. Front. Neurosci. 2018;12:80. doi: 10.3389/fnins.2018.00080.", "ArticleIdList": ["10.3389/fnins.2018.00080", "PMC5825910", "29515354"]}, {"Citation": "Rocha Cabrero F., Morrison E.H. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Lewy Bodies.", "ArticleIdList": ["30725641"]}, {"Citation": "Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson\u2019s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007;27:494\u2013506. doi: 10.1111/j.1440-1789.2007.00803.x.", "ArticleIdList": ["10.1111/j.1440-1789.2007.00803.x", "18018486"]}, {"Citation": "Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov. Disord. 2006;21:2042\u20132051. doi: 10.1002/mds.21065.", "ArticleIdList": ["10.1002/mds.21065", "17078043"]}, {"Citation": "Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318:121\u2013134. doi: 10.1007/s00441-004-0956-9.", "ArticleIdList": ["10.1007/s00441-004-0956-9", "15338272"]}, {"Citation": "McKeith I.G., Dickson D.W., Lowe J., Emre M., O\u2019Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology. 2005;65:1863\u20131872. doi: 10.1212/01.wnl.0000187889.17253.b1.", "ArticleIdList": ["10.1212/01.wnl.0000187889.17253.b1", "16237129"]}, {"Citation": "Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years. Mov. Disord. 2008;23:837\u2013844. doi: 10.1002/mds.21956.", "ArticleIdList": ["10.1002/mds.21956", "18307261"]}, {"Citation": "Del Tredici K., Braak H. Lewy pathology and neurodegeneration in premotor Parkinson\u2019s disease. Mov. Disord. 2012;27:597\u2013607. doi: 10.1002/mds.24921.", "ArticleIdList": ["10.1002/mds.24921", "22508278"]}, {"Citation": "Olanow C.W. The pathogenesis of cell death in Parkinson\u2019s disease\u20142007. Mov. Disord. 2007;22((Suppl. 17)):S335\u2013S342. doi: 10.1002/mds.21675.", "ArticleIdList": ["10.1002/mds.21675", "18175394"]}, {"Citation": "Elder G.J., Lazar A.S., Alfonso-Miller P., Taylor J.P. Sleep disturbances in Lewy body dementia: A systematic review. Int. J. Geriatr. Psychiatry. 2022;37:1\u201322. doi: 10.1002/gps.5814.", "ArticleIdList": ["10.1002/gps.5814", "PMC9827922", "36168299"]}, {"Citation": "Ferman T.J., Boeve B.F. Psychiatry of Parkinson\u2019s Disease. Volume 27. Karger Publishers; Basel, Switzerland: 2012. Sleep in Parkinson\u2019s disease and dementia with lewy bodies; pp. 61\u201370."}, {"Citation": "Poewe W., Hogl B. Parkinson\u2019s disease and sleep. Curr. Opin. Neurol. 2000;13:423\u2013426. doi: 10.1097/00019052-200008000-00009.", "ArticleIdList": ["10.1097/00019052-200008000-00009", "10970059"]}, {"Citation": "Poewe W., Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson\u2019s disease. Neurology. 2004;63:S12\u2013S16. doi: 10.1212/WNL.63.8_suppl_3.S12.", "ArticleIdList": ["10.1212/WNL.63.8_suppl_3.S12", "15505135"]}, {"Citation": "Stefani A., Hogl B. Sleep in Parkinson\u2019s disease. Neuropsychopharmacology. 2020;45:121\u2013128. doi: 10.1038/s41386-019-0448-y.", "ArticleIdList": ["10.1038/s41386-019-0448-y", "PMC6879568", "31234200"]}, {"Citation": "Tholfsen L.K., Larsen J.P., Schulz J., Tysnes O.B., Gjerstad M.D. Changes in insomnia subtypes in early Parkinson disease. Neurology. 2017;88:352\u2013358. doi: 10.1212/WNL.0000000000003540.", "ArticleIdList": ["10.1212/WNL.0000000000003540", "27986876"]}, {"Citation": "Monaca C., Duhamel A., Jacquesson J.M., Ozsancak C., Destee A., Guieu J.D., Defebvre L., Derambure P. Vigilance troubles in Parkinson\u2019s disease: A subjective and objective polysomnographic study. Sleep. Med. 2006;7:448\u2013453. doi: 10.1016/j.sleep.2005.12.002.", "ArticleIdList": ["10.1016/j.sleep.2005.12.002", "16740409"]}, {"Citation": "Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908\u20131910. doi: 10.1212/WNL.52.9.1908.", "ArticleIdList": ["10.1212/WNL.52.9.1908", "10371546"]}, {"Citation": "Loddo G., Calandra-Buonaura G., Sambati L., Giannini G., Cecere A., Cortelli P., Provini F. The Treatment of Sleep Disorders in Parkinson\u2019s Disease: From Research to Clinical Practice. Front. Neurol. 2017;8:42. doi: 10.3389/fneur.2017.00042.", "ArticleIdList": ["10.3389/fneur.2017.00042", "PMC5311042", "28261151"]}, {"Citation": "Ray Chaudhuri K., Martinez-Martin P., Rolfe K.A., Cooper J., Rockett C.B., Giorgi L., Ondo W.G. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson\u2019s disease. Eur. J. Neurol. 2012;19:105\u2013113. doi: 10.1111/j.1468-1331.2011.03442.x.", "ArticleIdList": ["10.1111/j.1468-1331.2011.03442.x", "21699627"]}, {"Citation": "Martinez-Ramirez D., De Jesus S., Walz R., Cervantes-Arriaga A., Peng-Chen Z., Okun M.S., Alatriste-Booth V., Rodriguez-Violante M. A Polysomnographic Study of Parkinson\u2019s Disease Sleep Architecture. Parkinson\u2019s Dis. 2015;2015:570375. doi: 10.1155/2015/570375.", "ArticleIdList": ["10.1155/2015/570375", "PMC4609478", "26504612"]}, {"Citation": "Pont-Sunyer C., Iranzo A., Gaig C., Fernandez-Arcos A., Vilas D., Valldeoriola F., Compta Y., Fernandez-Santiago R., Fernandez M., Bayes A., et al. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. PLoS ONE. 2015;10:e0132368. doi: 10.1371/journal.pone.0132368.", "ArticleIdList": ["10.1371/journal.pone.0132368", "PMC4503402", "26177462"]}, {"Citation": "O\u2019Dowd S., Galna B., Morris R., Lawson R.A., McDonald C., Yarnall A.J., Burn D.J., Rochester L., Anderson K.N. Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson\u2019s Disease Cohort. J. Park. Dis. 2017;7:465\u2013470. doi: 10.3233/JPD-161062.", "ArticleIdList": ["10.3233/JPD-161062", "28671141"]}, {"Citation": "Brunner H., Wetter T.C., Hogl B., Yassouridis A., Trenkwalder C., Friess E. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson\u2019s disease: Effects of dopaminergic treatment. Mov. Disord. 2002;17:928\u2013933. doi: 10.1002/mds.10242.", "ArticleIdList": ["10.1002/mds.10242", "12360541"]}, {"Citation": "Emser W., Brenner M., Stober T., Schimrigk K. Changes in nocturnal sleep in Huntington\u2019s and Parkinson\u2019s disease. J. Neurol. 1988;235:177\u2013179. doi: 10.1007/BF00314313.", "ArticleIdList": ["10.1007/BF00314313", "2966851"]}, {"Citation": "Chahine L.M., Amara A.W., Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson\u2019s disease from 2005 to 2015. Sleep. Med. Rev. 2017;35:33\u201350. doi: 10.1016/j.smrv.2016.08.001.", "ArticleIdList": ["10.1016/j.smrv.2016.08.001", "PMC5332351", "27863901"]}, {"Citation": "Gao J., Huang X., Park Y., Hollenbeck A., Blair A., Schatzkin A., Chen H. Daytime napping, nighttime sleeping, and Parkinson disease. Am. J. Epidemiol. 2011;173:1032\u20131038. doi: 10.1093/aje/kwq478.", "ArticleIdList": ["10.1093/aje/kwq478", "PMC3121222", "21402730"]}, {"Citation": "Ylikoski A., Martikainen K., Sieminski M., Partinen M. Parkinson\u2019s disease and insomnia. Neurol. Sci. 2015;36:2003\u20132010. doi: 10.1007/s10072-015-2288-9.", "ArticleIdList": ["10.1007/s10072-015-2288-9", "26099862"]}, {"Citation": "Wallace D.M., Wohlgemuth W.K., Trotti L.M., Amara A.W., Malaty I.A., Factor S.A., Nallu S., Wittine L., Hauser R.A. Practical Evaluation and Management of Insomnia in Parkinson\u2019s Disease: A Review. Mov. Disord. Clin. Pract. 2020;7:250\u2013266. doi: 10.1002/mdc3.12899.", "ArticleIdList": ["10.1002/mdc3.12899", "PMC7111581", "32258222"]}, {"Citation": "Louter M., van Sloun R.J., Pevernagie D.A., Arends J.B., Cluitmans P.J., Bloem B.R., Overeem S. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency. Sleep. Med. 2013;14:668\u2013674. doi: 10.1016/j.sleep.2013.03.010.", "ArticleIdList": ["10.1016/j.sleep.2013.03.010", "23643658"]}, {"Citation": "Poewe W. Non-motor symptoms in Parkinson\u2019s disease. Eur. J. Neurol. 2008;15((Suppl. 1)):14\u201320. doi: 10.1111/j.1468-1331.2008.02056.x.", "ArticleIdList": ["10.1111/j.1468-1331.2008.02056.x", "18353132"]}, {"Citation": "Rana A.Q., Qureshi A.R.M., Shamli Oghli Y., Saqib Y., Mohammed B., Sarfraz Z., Rana R. Decreased sleep quality in Parkinson\u2019s patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality. Neurol. Res. 2018;40:696\u2013701. doi: 10.1080/01616412.2018.1462880.", "ArticleIdList": ["10.1080/01616412.2018.1462880", "29663852"]}, {"Citation": "Palmeri R., Lo Buono V., Bonanno L., Sorbera C., Cimino V., Bramanti P., Di Lorenzo G., Marino S. Potential predictors of quality of life in Parkinson\u2019s Disease: Sleep and mood disorders. J. Clin. Neurosci. 2019;70:113\u2013117. doi: 10.1016/j.jocn.2019.08.058.", "ArticleIdList": ["10.1016/j.jocn.2019.08.058", "31421992"]}, {"Citation": "Kay D.B., Tanner J.J., Bowers D. Sleep disturbances and depression severity in patients with Parkinson\u2019s disease. Brain Behav. 2018;8:e00967. doi: 10.1002/brb3.967.", "ArticleIdList": ["10.1002/brb3.967", "PMC5991567", "30106239"]}, {"Citation": "Breen D.P., Vuono R., Nawarathna U., Fisher K., Shneerson J.M., Reddy A.B., Barker R.A. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589\u2013595. doi: 10.1001/jamaneurol.2014.65.", "ArticleIdList": ["10.1001/jamaneurol.2014.65", "PMC4119609", "24687146"]}, {"Citation": "Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., Destee A. Study of circadian melatonin secretion pattern at different stages of Parkinson\u2019s disease. Clin. Neuropharmacol. 2003;26:65\u201372. doi: 10.1097/00002826-200303000-00005.", "ArticleIdList": ["10.1097/00002826-200303000-00005", "12671525"]}, {"Citation": "Hartmann A., Veldhuis J.D., Deuschle M., Standhardt H., Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer\u2019s and Parkinson\u2019s disease compared to normal controls: Ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging. 1997;18:285\u2013289. doi: 10.1016/S0197-4580(97)80309-0.", "ArticleIdList": ["10.1016/S0197-4580(97)80309-0", "9263193"]}, {"Citation": "Hunt J., Coulson E.J., Rajnarayanan R., Oster H., Videnovic A., Rawashdeh O. Sleep and circadian rhythms in Parkinson\u2019s disease and preclinical models. Mol. Neurodegener. 2022;17:2. doi: 10.1186/s13024-021-00504-w.", "ArticleIdList": ["10.1186/s13024-021-00504-w", "PMC8744293", "35000606"]}, {"Citation": "Yang Z., Zhang X., Li C., Chi S., Xie A. Molecular Mechanisms Underlying Reciprocal Interactions Between Sleep Disorders and Parkinson\u2019s Disease. Front. Neurosci. 2020;14:592989. doi: 10.3389/fnins.2020.592989.", "ArticleIdList": ["10.3389/fnins.2020.592989", "PMC7902929", "33642969"]}, {"Citation": "Schutz L., Sixel-Doring F., Hermann W. Management of Sleep Disturbances in Parkinson\u2019s Disease. J. Parkinson\u2019s Dis. 2022;12:2029\u20132058. doi: 10.3233/JPD-212749.", "ArticleIdList": ["10.3233/JPD-212749", "PMC9661340", "35938257"]}, {"Citation": "Vaseghi S., Arjmandi-Rad S., Eskandari M., Ebrahimnejad M., Kholghi G., Zarrindast M.R. Modulating role of serotonergic signaling in sleep and memory. Pharmacol. Rep. 2022;74:1\u201326. doi: 10.1007/s43440-021-00339-8.", "ArticleIdList": ["10.1007/s43440-021-00339-8", "34743316"]}, {"Citation": "Arjmandi-Rad S., Ebrahimnejad M., Zarrindast M.R., Vaseghi S. Do Sleep Disturbances have a Dual Effect on Alzheimer\u2019s Disease? Cell. Mol. Neurobiol. 2022;43:711\u2013727. doi: 10.1007/s10571-022-01228-1.", "ArticleIdList": ["10.1007/s10571-022-01228-1", "35568778"]}, {"Citation": "Hogl B.E., Gomez-Arevalo G., Garcia S., Scipioni O., Rubio M., Blanco M., Gershanik O.S. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson\u2019s disease. Neurology. 1998;50:1332\u20131339. doi: 10.1212/wnl.50.5.1332.", "ArticleIdList": ["10.1212/wnl.50.5.1332", "9595983"]}, {"Citation": "Agid Y., Cervera P., Hirsch E., Javoy-Agid F., Lehericy S., Raisman R., Ruberg M. Biochemistry of Parkinson\u2019s disease 28 years later: A critical review. Mov. Disord. 1989;4((Suppl. 1)):S126\u2013S144. doi: 10.1002/mds.870040514.", "ArticleIdList": ["10.1002/mds.870040514", "2566912"]}, {"Citation": "Menza M., Dobkin R.D., Marin H., Bienfait K. Sleep disturbances in Parkinson\u2019s disease. Mov. Disord. 2010;25((Suppl. 1)):S117\u2013S122. doi: 10.1002/mds.22788.", "ArticleIdList": ["10.1002/mds.22788", "PMC2840057", "20187236"]}, {"Citation": "Qu W.M., Xu X.H., Yan M.M., Wang Y.Q., Urade Y., Huang Z.L. Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice. J. Neurosci. 2010;30:4382\u20134389. doi: 10.1523/JNEUROSCI.4936-09.2010.", "ArticleIdList": ["10.1523/JNEUROSCI.4936-09.2010", "PMC6634511", "20335474"]}, {"Citation": "Andretic R., van Swinderen B., Greenspan R.J. Dopaminergic modulation of arousal in Drosophila. Curr. Biol. 2005;15:1165\u20131175. doi: 10.1016/j.cub.2005.05.025.", "ArticleIdList": ["10.1016/j.cub.2005.05.025", "16005288"]}, {"Citation": "Rothman S.M., Mattson M.P. Sleep disturbances in Alzheimer\u2019s and Parkinson\u2019s diseases. Neuromolecular Med. 2012;14:194\u2013204. doi: 10.1007/s12017-012-8181-2.", "ArticleIdList": ["10.1007/s12017-012-8181-2", "PMC4544709", "22552887"]}, {"Citation": "Monti J.M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev. 2007;11:113\u2013133. doi: 10.1016/j.smrv.2006.08.003.", "ArticleIdList": ["10.1016/j.smrv.2006.08.003", "17275369"]}, {"Citation": "Lena I., Parrot S., Deschaux O., Muffat-Joly S., Sauvinet V., Renaud B., Suaud-Chagny M.F., Gottesmann C. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep\u2013wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J. Neurosci. Res. 2005;81:891\u2013899. doi: 10.1002/jnr.20602.", "ArticleIdList": ["10.1002/jnr.20602", "16041801"]}, {"Citation": "Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004;74:1\u201358. doi: 10.1016/j.pneurobio.2004.05.006.", "ArticleIdList": ["10.1016/j.pneurobio.2004.05.006", "15381316"]}, {"Citation": "Monte-Silva K., Kuo M.F., Thirugnanasambandam N., Liebetanz D., Paulus W., Nitsche M.A. Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. J. Neurosci. 2009;29:6124\u20136131. doi: 10.1523/JNEUROSCI.0728-09.2009.", "ArticleIdList": ["10.1523/JNEUROSCI.0728-09.2009", "PMC6665507", "19439590"]}, {"Citation": "Kalaitzakis M.E., Gentleman S.M., Pearce R.K. Disturbed sleep in Parkinson\u2019s disease: Anatomical and pathological correlates. Neuropathol. Appl. Neurobiol. 2013;39:644\u2013653. doi: 10.1111/nan.12024.", "ArticleIdList": ["10.1111/nan.12024", "23363035"]}, {"Citation": "Reeves W.C., Heim C., Maloney E.M., Youngblood L.S., Unger E.R., Decker M.J., Jones J.F., Rye D.B. Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: Results from a population-based study. BMC Neurol. 2006;6:41. doi: 10.1186/1471-2377-6-41.", "ArticleIdList": ["10.1186/1471-2377-6-41", "PMC1660569", "17109739"]}, {"Citation": "Fifel K., Cooper H.M. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson\u2019s disease. Neurobiol. Dis. 2014;71:359\u2013369. doi: 10.1016/j.nbd.2014.08.024.", "ArticleIdList": ["10.1016/j.nbd.2014.08.024", "25171792"]}, {"Citation": "Bohnen N.I., Hu M.T.M. Sleep Disturbance as Potential Risk and Progression Factor for Parkinson\u2019s Disease. J. Park. Dis. 2019;9:603\u2013614. doi: 10.3233/JPD-191627.", "ArticleIdList": ["10.3233/JPD-191627", "PMC6700634", "31227656"]}, {"Citation": "Kress B.T., Iliff J.J., Xia M., Wang M., Wei H.S., Zeppenfeld D., Xie L., Kang H., Xu Q., Liew J.A., et al. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 2014;76:845\u2013861. doi: 10.1002/ana.24271.", "ArticleIdList": ["10.1002/ana.24271", "PMC4245362", "25204284"]}, {"Citation": "Hablitz L.M., Vinitsky H.S., Sun Q., Staeger F.F., Sigurdsson B., Mortensen K.N., Lilius T.O., Nedergaard M. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci. Adv. 2019;5:eaav5447. doi: 10.1126/sciadv.aav5447.", "ArticleIdList": ["10.1126/sciadv.aav5447", "PMC6392807", "30820460"]}, {"Citation": "Svetnik V., Snyder E.S., Ma J., Tao P., Lines C., Herring W.J. EEG spectral analysis of NREM sleep in a large sample of patients with insomnia and good sleepers: Effects of age, sex and part of the night. J. Sleep. Res. 2017;26:92\u2013104. doi: 10.1111/jsr.12448.", "ArticleIdList": ["10.1111/jsr.12448", "27634437"]}, {"Citation": "Ksendzovsky A., Pomeraniec I.J., Zaghloul K.A., Provencio J.J., Provencio I. Clinical implications of the melanopsin-based non-image-forming visual system. Neurology. 2017;88:1282\u20131290. doi: 10.1212/WNL.0000000000003761.", "ArticleIdList": ["10.1212/WNL.0000000000003761", "PMC5373779", "28251921"]}, {"Citation": "La Morgia C., Ross-Cisneros F.N., Sadun A.A., Carelli V. Retinal Ganglion Cells and Circadian Rhythms in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Beyond. Front. Neurol. 2017;8:162. doi: 10.3389/fneur.2017.00162.", "ArticleIdList": ["10.3389/fneur.2017.00162", "PMC5415575", "28522986"]}, {"Citation": "Ortuno-Lizaran I., Esquiva G., Beach T.G., Serrano G.E., Adler C.H., Lax P., Cuenca N. Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson\u2019s disease. Acta Neuropathol. Commun. 2018;6:90. doi: 10.1186/s40478-018-0596-z.", "ArticleIdList": ["10.1186/s40478-018-0596-z", "PMC6130068", "30201049"]}, {"Citation": "Ortu\u00f1o-Lizar\u00e1n I., S\u00e1nchez-S\u00e1ez X., Lax P., Serrano G.E., Beach T.G., Adler C.H., Cuenca N. Dopaminergic retinal cell loss and visual dysfunction in Parkinson disease. Ann. Neurol. 2020;88:893\u2013906. doi: 10.1002/ana.25897.", "ArticleIdList": ["10.1002/ana.25897", "PMC10005860", "32881029"]}, {"Citation": "Liao H.W., Ren X., Peterson B.B., Marshak D.W., Yau K.W., Gamlin P.D., Dacey D.M. Melanopsin-expressing ganglion cells on macaque and human retinas form two morphologically distinct populations. J. Comp. Neurol. 2016;524:2845\u20132872. doi: 10.1002/cne.23995.", "ArticleIdList": ["10.1002/cne.23995", "PMC4970949", "26972791"]}, {"Citation": "Van Hook M.J., Wong K.Y., Berson D.M. Dopaminergic modulation of ganglion-cell photoreceptors in rat. Eur. J. Neurosci. 2012;35:507\u2013518. doi: 10.1111/j.1460-9568.2011.07975.x.", "ArticleIdList": ["10.1111/j.1460-9568.2011.07975.x", "PMC3339262", "22304466"]}, {"Citation": "Prigge C.L., Yeh P.T., Liou N.F., Lee C.C., You S.F., Liu L.L., McNeill D.S., Chew K.S., Hattar S., Chen S.K., et al. M1 ipRGCs Influence Visual Function through Retrograde Signaling in the Retina. J. Neurosci. 2016;36:7184\u20137197. doi: 10.1523/JNEUROSCI.3500-15.2016.", "ArticleIdList": ["10.1523/JNEUROSCI.3500-15.2016", "PMC4938862", "27383593"]}, {"Citation": "Neikrug A.B., Maglione J.E., Liu L., Natarajan L., Avanzino J.A., Corey-Bloom J., Palmer B.W., Loredo J.S., Ancoli-Israel S. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J. Clin. Sleep. Med. 2013;9:1119\u20131129. doi: 10.5664/jcsm.3148.", "ArticleIdList": ["10.5664/jcsm.3148", "PMC3805796", "24235892"]}, {"Citation": "Gros P., Videnovic A. Sleep and Circadian Rhythm Disorders in Parkinson\u2019s Disease. Curr. Sleep. Med. Rep. 2017;3:222\u2013234. doi: 10.1007/s40675-017-0079-y.", "ArticleIdList": ["10.1007/s40675-017-0079-y", "PMC5699506", "29177129"]}, {"Citation": "Gan-Or Z., Alcalay R.N., Rouleau G.A., Postuma R.B. Sleep disorders and Parkinson disease; lessons from genetics. Sleep. Med. Rev. 2018;41:101\u2013112. doi: 10.1016/j.smrv.2018.01.006.", "ArticleIdList": ["10.1016/j.smrv.2018.01.006", "29449121"]}, {"Citation": "Luppi P.H., Clement O., Valencia Garcia S., Brischoux F., Fort P. New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: The potential role of glutamate, \u03b3-aminobutyric acid, and glycine. Sleep Med. 2013;14:714\u2013718. doi: 10.1016/j.sleep.2013.02.004.", "ArticleIdList": ["10.1016/j.sleep.2013.02.004", "23790501"]}, {"Citation": "De Cock V.C., Vidailhet M., Leu S., Texeira A., Apartis E., Elbaz A., Roze E., Willer J.C., Derenne J.P., Agid Y., et al. Restoration of normal motor control in Parkinson\u2019s disease during REM sleep. Brain. 2007;130:450\u2013456. doi: 10.1093/brain/awl363.", "ArticleIdList": ["10.1093/brain/awl363", "17235126"]}, {"Citation": "Boeve B.F. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann. N. Y. Acad. Sci. 2010;1184:15\u201354. doi: 10.1111/j.1749-6632.2009.05115.x.", "ArticleIdList": ["10.1111/j.1749-6632.2009.05115.x", "PMC2902006", "20146689"]}, {"Citation": "Hu M.T. REM sleep behavior disorder (RBD) Neurobiol. Dis. 2020;143:104996. doi: 10.1016/j.nbd.2020.104996.", "ArticleIdList": ["10.1016/j.nbd.2020.104996", "32599063"]}, {"Citation": "Zhang X., Sun X., Wang J., Tang L., Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson\u2019s disease: A meta and meta-regression analysis. Neurol. Sci. 2017;38:163\u2013170. doi: 10.1007/s10072-016-2744-1.", "ArticleIdList": ["10.1007/s10072-016-2744-1", "27770275"]}, {"Citation": "Iranzo A., Santamaria J., Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med. Rev. 2009;13:385\u2013401. doi: 10.1016/j.smrv.2008.11.003.", "ArticleIdList": ["10.1016/j.smrv.2008.11.003", "19362028"]}, {"Citation": "Kim Y.E., Jeon B.S. Clinical implication of REM sleep behavior disorder in Parkinson\u2019s disease. J. Park. Dis. 2014;4:237\u2013244. doi: 10.3233/JPD-130293.", "ArticleIdList": ["10.3233/JPD-130293", "24613864"]}, {"Citation": "Diaconu S., Falup-Pecurariu O., Tint D., Falup-Pecurariu C. REM sleep behaviour disorder in Parkinson\u2019s disease (Review) Exp. Ther. Med. 2021;22:812. doi: 10.3892/etm.2021.10244.", "ArticleIdList": ["10.3892/etm.2021.10244", "PMC8193212", "34131435"]}, {"Citation": "Pagano G., De Micco R., Yousaf T., Wilson H., Chandra A., Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91:e894\u2013e905. doi: 10.1212/WNL.0000000000006134.", "ArticleIdList": ["10.1212/WNL.0000000000006134", "30089615"]}, {"Citation": "Linn-Evans M.E., Petrucci M.N., Amundsen Huffmaster S.L., Chung J.W., Tuite P.J., Howell M.J., Videnovic A., MacKinnon C.D. REM sleep without atonia is associated with increased rigidity in patients with mild to moderate Parkinson\u2019s disease. Clin. Neurophysiol. 2020;131:2008\u20132016. doi: 10.1016/j.clinph.2020.04.017.", "ArticleIdList": ["10.1016/j.clinph.2020.04.017", "PMC7363578", "32451296"]}, {"Citation": "Postuma R.B., Gagnon J.F., Vendette M., Charland K., Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov. Disord. 2008;23:1665\u20131672. doi: 10.1002/mds.22099.", "ArticleIdList": ["10.1002/mds.22099", "18709686"]}, {"Citation": "Gagnon J.F., Fantini M.L., Bedard M.A., Petit D., Carrier J., Rompre S., Decary A., Panisset M., Montplaisir J. Association between waking EEG slowing and REM sleep behavior disorder in PD without dementia. Neurology. 2004;62:401\u2013406. doi: 10.1212/01.WNL.0000106460.34682.E9.", "ArticleIdList": ["10.1212/01.WNL.0000106460.34682.E9", "14872020"]}, {"Citation": "Postuma R.B., Lang A.E., Gagnon J.F., Pelletier A., Montplaisir J.Y. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012;135:1860\u20131870. doi: 10.1093/brain/aws093.", "ArticleIdList": ["10.1093/brain/aws093", "22561644"]}, {"Citation": "Marques A., Dujardin K., Boucart M., Pins D., Delliaux M., Defebvre L., Derambure P., Monaca C. REM sleep behaviour disorder and visuoperceptive dysfunction: A disorder of the ventral visual stream? J. Neurol. 2010;257:383\u2013391. doi: 10.1007/s00415-009-5328-7.", "ArticleIdList": ["10.1007/s00415-009-5328-7", "19789940"]}, {"Citation": "Zhang J.R., Chen J., Yang Z.J., Zhang H.J., Fu Y.T., Shen Y., He P.C., Mao C.J., Liu C.F. Rapid Eye Movement Sleep Behavior Disorder Symptoms Correlate with Domains of Cognitive Impairment in Parkinson\u2019s Disease. Chin. Med. J. 2016;129:379\u2013385. doi: 10.4103/0366-6999.176077.", "ArticleIdList": ["10.4103/0366-6999.176077", "PMC4800836", "26879009"]}, {"Citation": "Mahmood Z., Van Patten R., Nakhla M.Z., Twamley E.W., Filoteo J.V., Schiehser D.M. REM Sleep Behavior Disorder in Parkinson\u2019s Disease: Effects on Cognitive, Psychiatric, and Functional outcomes. J. Int. Neuropsychol. Soc. 2020;26:894\u2013905. doi: 10.1017/S1355617720000430.", "ArticleIdList": ["10.1017/S1355617720000430", "PMC7554050", "32375913"]}, {"Citation": "Garcia S.V., Brischoux F., Cl\u00e9ment O., Libourel P.-A., Arthaud S., Lazarus M., Luppi P.-H., Fort P. Ventromedial medulla inhibitory neuron inactivation induces REM sleep without atonia and REM sleep behavior disorder. Nat. Commun. 2018;9:504. doi: 10.1038/s41467-017-02761-0.", "ArticleIdList": ["10.1038/s41467-017-02761-0", "PMC5799338", "29402935"]}, {"Citation": "Weber F., Chung S., Beier K.T., Xu M., Luo L., Dan Y. Control of REM sleep by ventral medulla GABAergic neurons. Nature. 2015;526:435\u2013438. doi: 10.1038/nature14979.", "ArticleIdList": ["10.1038/nature14979", "PMC4852286", "26444238"]}, {"Citation": "Slow E.J., Postuma R.B., Lang A.E. Implications of nocturnal symptoms towards the early diagnosis of Parkinson\u2019s disease. J. Neural Transm. 2014;121((Suppl. 1)):S49\u2013S57. doi: 10.1007/s00702-014-1168-4.", "ArticleIdList": ["10.1007/s00702-014-1168-4", "24500032"]}, {"Citation": "Garcia-Lorenzo D., Longo-Dos Santos C., Ewenczyk C., Leu-Semenescu S., Gallea C., Quattrocchi G., Pita Lobo P., Poupon C., Benali H., Arnulf I., et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson\u2019s disease. Brain. 2013;136:2120\u20132129. doi: 10.1093/brain/awt152.", "ArticleIdList": ["10.1093/brain/awt152", "PMC3692035", "23801736"]}, {"Citation": "Salsone M., Cerasa A., Arabia G., Morelli M., Gambardella A., Mumoli L., Nistico R., Vescio B., Quattrone A. Reduced thalamic volume in Parkinson disease with REM sleep behavior disorder: Volumetric study. Park. Relat. Disord. 2014;20:1004\u20131008. doi: 10.1016/j.parkreldis.2014.06.012.", "ArticleIdList": ["10.1016/j.parkreldis.2014.06.012", "24998995"]}, {"Citation": "Iwanami M., Miyamoto T., Miyamoto M., Hirata K., Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med. 2010;11:361\u2013365. doi: 10.1016/j.sleep.2009.12.006.", "ArticleIdList": ["10.1016/j.sleep.2009.12.006", "20223708"]}, {"Citation": "Lim J.S., Shin S.A., Lee J.Y., Nam H., Lee J.Y., Kim Y.K. Neural substrates of rapid eye movement sleep behavior disorder in Parkinson\u2019s disease. Park. Relat. Disord. 2016;23:31\u201336. doi: 10.1016/j.parkreldis.2015.11.027.", "ArticleIdList": ["10.1016/j.parkreldis.2015.11.027", "26678512"]}, {"Citation": "Brooks P.L., Peever J.H. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J. Neurosci. 2011;31:7111\u20137121. doi: 10.1523/JNEUROSCI.0347-11.2011.", "ArticleIdList": ["10.1523/JNEUROSCI.0347-11.2011", "PMC6703223", "21562273"]}, {"Citation": "Yadav R.K., Khanday M.A., Mallick B.N. Interplay of dopamine and GABA in substantia nigra for the regulation of rapid eye movement sleep in rats. Behav. Brain Res. 2019;376:112169. doi: 10.1016/j.bbr.2019.112169.", "ArticleIdList": ["10.1016/j.bbr.2019.112169", "31442548"]}, {"Citation": "Brooks P.L., Peever J.H. Glycinergic and GABA(A)-mediated inhibition of somatic motoneurons does not mediate rapid eye movement sleep motor atonia. J. Neurosci. 2008;28:3535\u20133545. doi: 10.1523/JNEUROSCI.5023-07.2008.", "ArticleIdList": ["10.1523/JNEUROSCI.5023-07.2008", "PMC6671096", "18385312"]}, {"Citation": "Kryger M.H., Roth T., Dement W.C. Principles and Practice of Sleep. Medicine E-Book. Elsevier Health Sciences; Philadelphia, PA, USA: 2010."}, {"Citation": "Martinelli P., Nassetti S., Minardi C., Macri S., Ippoliti M. Electrophysiological evaluation of the stiff-man syndrome: Further data. J. Neurol. 1996;243:551\u2013553. doi: 10.1007/BF00886879.", "ArticleIdList": ["10.1007/BF00886879", "8836947"]}, {"Citation": "de Groen J.H., Kamphuisen H.A. Periodic nocturnal myoclonus in a patient with hyperexplexia (startle disease) J. Neurol. Sci. 1978;38:207\u2013213. doi: 10.1016/0022-510X(78)90067-9.", "ArticleIdList": ["10.1016/0022-510X(78)90067-9", "213539"]}, {"Citation": "Schenck C.H., Mahowald M.W. REM sleep behavior disorder: Clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002;25:120\u2013138. doi: 10.1093/sleep/25.2.120.", "ArticleIdList": ["10.1093/sleep/25.2.120", "11902423"]}, {"Citation": "Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123 (Pt. 2):331\u2013339. doi: 10.1093/brain/123.2.331.", "ArticleIdList": ["10.1093/brain/123.2.331", "10648440"]}, {"Citation": "Koch J., Willemsen K., Dogan I., Rolke R., Schulz J.B., Schiefer J., Reetz K., Maier A. Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder\u2014A clue to early peripheral autonomic and sensory dysfunction? J. Neurol. 2022;269:923\u2013932. doi: 10.1007/s00415-021-10675-7.", "ArticleIdList": ["10.1007/s00415-021-10675-7", "PMC8782803", "34170404"]}, {"Citation": "Uchiyama M., Isse K., Tanaka K., Yokota N., Hamamoto M., Aida S., Ito Y., Yoshimura M., Okawa M. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 1995;45:709\u2013712. doi: 10.1212/WNL.45.4.709.", "ArticleIdList": ["10.1212/WNL.45.4.709", "7723959"]}, {"Citation": "Mattioli P., Pardini M., Fama F., Girtler N., Brugnolo A., Orso B., Meli R., Filippi L., Grisanti S., Massa F., et al. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2834\u20132845. doi: 10.1007/s00259-021-05205-6.", "ArticleIdList": ["10.1007/s00259-021-05205-6", "33511424"]}, {"Citation": "Stokholm M.G., Iranzo A., Ostergaard K., Serradell M., Otto M., Bacher Svendsen K., Garrido A., Vilas D., Parbo P., Borghammer P., et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol. Dis. 2018;115:9\u201316. doi: 10.1016/j.nbd.2018.02.017.", "ArticleIdList": ["10.1016/j.nbd.2018.02.017", "29522818"]}, {"Citation": "Miyamoto M., Miyamoto T., Iwanami M., Muramatsu S., Asari S., Nakano I., Hirata K. Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder. Sleep. Med. 2012;13:102\u2013106. doi: 10.1016/j.sleep.2011.03.024.", "ArticleIdList": ["10.1016/j.sleep.2011.03.024", "22033122"]}, {"Citation": "Iranzo A., Santamaria J., Valldeoriola F., Serradell M., Salamero M., Gaig C., Ninerola-Baizan A., Sanchez-Valle R., Llado A., De Marzi R., et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 2017;82:419\u2013428. doi: 10.1002/ana.25026.", "ArticleIdList": ["10.1002/ana.25026", "28833467"]}, {"Citation": "Shin J.H., Lee J.Y., Kim Y.K., Shin S.A., Kim H., Nam H., Jeon B. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology. 2020;95:e3081\u2013e3092. doi: 10.1212/WNL.0000000000010942.", "ArticleIdList": ["10.1212/WNL.0000000000010942", "32989104"]}, {"Citation": "Zoetmulder M., Nikolic M., Biernat H., Korbo L., Friberg L., Jennum P. Increased Motor Activity During REM Sleep Is Linked with Dopamine Function in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. J. Clin. Sleep. Med. 2016;12:895\u2013903. doi: 10.5664/jcsm.5896.", "ArticleIdList": ["10.5664/jcsm.5896", "PMC4877323", "27070245"]}, {"Citation": "Lai Y.Y., Siegel J.M. Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation. J. Neurosci. 1990;10:2727\u20132734. doi: 10.1523/JNEUROSCI.10-08-02727.1990.", "ArticleIdList": ["10.1523/JNEUROSCI.10-08-02727.1990", "PMC6570267", "2388085"]}, {"Citation": "Teman P.T., Tippmann-Peikert M., Silber M.H., Slocumb N.L., Auger R.R. Idiopathic rapid-eye-movement sleep disorder: Associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10:60\u201365. doi: 10.1016/j.sleep.2007.11.019.", "ArticleIdList": ["10.1016/j.sleep.2007.11.019", "18226952"]}, {"Citation": "Schenck C.H., Mahowald M.W., Kim S.W., O\u2019Connor K.A., Hurwitz T.D. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep. 1992;15:226\u2013235. doi: 10.1093/sleep/15.3.226.", "ArticleIdList": ["10.1093/sleep/15.3.226", "1621023"]}, {"Citation": "Postuma R.B., Gagnon J.F., Tuineaig M., Bertrand J.A., Latreille V., Desjardins C., Montplaisir J.Y. Antidepressants and REM sleep behavior disorder: Isolated side effect or neurodegenerative signal? Sleep. 2013;36:1579\u20131585. doi: 10.5665/sleep.3102.", "ArticleIdList": ["10.5665/sleep.3102", "PMC3792373", "24179289"]}, {"Citation": "Sheyner I., Khan S., Stewart J.T. A case of selective serotonin reuptake inhibitor-induced rapid eye movement behavior disorder. J. Am. Geriatr. Soc. 2010;58:1421\u20131422. doi: 10.1111/j.1532-5415.2010.02947.x.", "ArticleIdList": ["10.1111/j.1532-5415.2010.02947.x", "20672438"]}, {"Citation": "Tan L., Zhou J., Yang L., Ren R., Zhang Y., Li T., Tang X. Duloxetine-induced rapid eye movement sleep behavior disorder: A case report. BMC Psychiatry. 2017;17:372. doi: 10.1186/s12888-017-1535-4.", "ArticleIdList": ["10.1186/s12888-017-1535-4", "PMC5698922", "29162053"]}, {"Citation": "Onofrj M., Luciano A.L., Thomas A., Iacono D., D\u2019Andreamatteo G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology. 2003;60:113\u2013115. doi: 10.1212/01.WNL.0000042084.03066.C0.", "ArticleIdList": ["10.1212/01.WNL.0000042084.03066.C0", "12525729"]}, {"Citation": "Jimenez-Jimenez F.J., Alonso-Navarro H., Garcia-Martin E., Agundez J.A.G. Neurochemical Features of Rem Sleep Behaviour Disorder. J. Pers. Med. 2021;11:880. doi: 10.3390/jpm11090880.", "ArticleIdList": ["10.3390/jpm11090880", "PMC8468296", "34575657"]}, {"Citation": "McCarter S.J., St Louis E.K., Sandness D.J., Arndt K., Erickson M., Tabatabai G., Boeve B.F., Silber M.H. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38:907\u2013917. doi: 10.5665/sleep.4738.", "ArticleIdList": ["10.5665/sleep.4738", "PMC4434557", "25325487"]}, {"Citation": "Bedard M.A., Aghourian M., Legault-Denis C., Postuma R.B., Soucy J.P., Gagnon J.F., Pelletier A., Montplaisir J. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: A PET imaging study with (18)F-FEOBV. Sleep Med. 2019;58:35\u201341. doi: 10.1016/j.sleep.2018.12.020.", "ArticleIdList": ["10.1016/j.sleep.2018.12.020", "31078078"]}, {"Citation": "Yeh S.B., Yeh P.Y., Schenck C.H. Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer\u2019s disease. J. Clin. Sleep Med. 2010;6:192\u2013195. doi: 10.5664/jcsm.27771.", "ArticleIdList": ["10.5664/jcsm.27771", "PMC2854709", "20411699"]}, {"Citation": "Gersel Stokholm M., Iranzo A., Ostergaard K., Serradell M., Otto M., Bacher Svendsen K., Garrido A., Vilas D., Fedorova T.D., Santamaria J., et al. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. Eur. J. Neurol. 2020;27:644\u2013652. doi: 10.1111/ene.14127.", "ArticleIdList": ["10.1111/ene.14127", "31725927"]}, {"Citation": "Staer K., Iranzo A., Stokholm M.G., Ostergaard K., Serradell M., Otto M., Svendsen K.B., Garrido A., Vilas D., Santamaria J., et al. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Park. Relat. Disord. 2020;81:89\u201393. doi: 10.1016/j.parkreldis.2020.10.014.", "ArticleIdList": ["10.1016/j.parkreldis.2020.10.014", "33099132"]}, {"Citation": "Kotagal V., Albin R.L., Muller M.L., Koeppe R.A., Chervin R.D., Frey K.A., Bohnen N.I. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 2012;71:560\u2013568. doi: 10.1002/ana.22691.", "ArticleIdList": ["10.1002/ana.22691", "PMC3727906", "22522445"]}, {"Citation": "Arnaldi D., Latimier A., Leu-Semenescu S., Vidailhet M., Arnulf I. Loss of REM sleep features across nighttime in REM sleep behavior disorder. Sleep Med. 2016;17:134\u2013137. doi: 10.1016/j.sleep.2015.10.019.", "ArticleIdList": ["10.1016/j.sleep.2015.10.019", "26847988"]}, {"Citation": "Weissova K., Skrabalova J., Skalova K., Cervena K., Bendova Z., Miletinova E., Koprivova J., Sonka K., Dudysova D., Bartos A., et al. Circadian rhythms of melatonin and peripheral clock gene expression in idiopathic REM sleep behavior disorder. Sleep Med. 2018;52:1\u20136. doi: 10.1016/j.sleep.2018.07.019.", "ArticleIdList": ["10.1016/j.sleep.2018.07.019", "30195196"]}, {"Citation": "Knudsen S., Gammeltoft S., Jennum P.J. Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. Brain. 2010;133:568\u2013579. doi: 10.1093/brain/awp320.", "ArticleIdList": ["10.1093/brain/awp320", "20129934"]}, {"Citation": "Van Dort C.J., Zachs D.P., Kenny J.D., Zheng S., Goldblum R.R., Gelwan N.A., Ramos D.M., Nolan M.A., Wang K., Weng F.-J. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc. Natl. Acad. Sci. USA. 2015;112:584\u2013589. doi: 10.1073/pnas.1423136112.", "ArticleIdList": ["10.1073/pnas.1423136112", "PMC4299243", "25548191"]}, {"Citation": "El Mansari M., Sakai K., Jouvet M. Responses of presumed cholinergic mesopontine tegmental neurons to carbachol microinjections in freely moving cats. Exp. Brain Res. 1990;83:115\u2013123. doi: 10.1007/BF00232199.", "ArticleIdList": ["10.1007/BF00232199", "2073933"]}, {"Citation": "Dos Santos A.B., Skaanning L.K., Mikkelsen E., Romero-Leguizam\u00f3n C.R., Kristensen M.P., Klein A.B., Thaneshwaran S., Langkilde A.E., Kohlmeier K.A. \u03b1-Synuclein responses in the laterodorsal tegmentum, the pedunculopontine tegmentum, and the substantia nigra: Implications for early appearance of sleep disorders in Parkinson\u2019s disease. J. Park. Dis. 2021;11:1773\u20131790. doi: 10.3233/JPD-212554.", "ArticleIdList": ["10.3233/JPD-212554", "34151857"]}, {"Citation": "Matzaras R., Shi K., Artemiadis A., Zis P., Hadjigeorgiou G., Rominger A., Bassetti C.L.A., Bargiotas P. Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson\u2019s Disease: A Systematic Review. J. Park. Dis. 2022;12:69\u201383. doi: 10.3233/JPD-212571.", "ArticleIdList": ["10.3233/JPD-212571", "34806615"]}, {"Citation": "Liu J., Shuai G., Fang W., Zhu Y., Chen H., Wang Y., Li Q., Han Y., Zou D., Cheng O. Altered regional homogeneity and connectivity in cerebellum and visual-motor relevant cortex in Parkinson\u2019s disease with rapid eye movement sleep behavior disorder. Sleep Med. 2021;82:125\u2013133. doi: 10.1016/j.sleep.2021.03.041.", "ArticleIdList": ["10.1016/j.sleep.2021.03.041", "33915428"]}, {"Citation": "Kwak I.H., Lee Y.K., Ma H.I., Lee S., Yun M., Kim Y.J., Hwang H.S., Kim Y.E. Striatal Subregion Analysis Associated with REM Sleep Behavior Disorder in Parkinson\u2019s Disease. J. Integr. Neurosci. 2023;22:18. doi: 10.31083/j.jin2201018.", "ArticleIdList": ["10.31083/j.jin2201018", "36722243"]}, {"Citation": "Kim H.J., Im H.K., Kim J., Han J.Y., de Leon M., Deshpande A., Moon W.J. Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease. J. Alzheimers Dis. 2016;52:1101\u20131109. doi: 10.3233/JAD-151197.", "ArticleIdList": ["10.3233/JAD-151197", "PMC5348920", "27060938"]}, {"Citation": "Ford A.H., Duncan G.W., Firbank M.J., Yarnall A.J., Khoo T.K., Burn D.J., O\u2019Brien J.T. Rapid eye movement sleep behavior disorder in Parkinson\u2019s disease: Magnetic resonance imaging study. Mov. Disord. 2013;28:832\u2013836. doi: 10.1002/mds.25367.", "ArticleIdList": ["10.1002/mds.25367", "23450684"]}, {"Citation": "Iranzo A., Tolosa E., Gelpi E., Molinuevo J.L., Valldeoriola F., Serradell M., Sanchez-Valle R., Vilaseca I., Lomena F., Vilas D., et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurol. 2013;12:443\u2013453. doi: 10.1016/S1474-4422(13)70056-5.", "ArticleIdList": ["10.1016/S1474-4422(13)70056-5", "23562390"]}, {"Citation": "Boucetta S., Salimi A., Dadar M., Jones B.E., Collins D.L., Dang-Vu T.T. Structural Brain Alterations Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson\u2019s Disease. Sci. Rep. 2016;6:26782. doi: 10.1038/srep26782.", "ArticleIdList": ["10.1038/srep26782", "PMC4887790", "27245317"]}, {"Citation": "Dauvilliers Y., Jennum P., Plazzi G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 2013;14:775\u2013781. doi: 10.1016/j.sleep.2012.10.006.", "ArticleIdList": ["10.1016/j.sleep.2012.10.006", "23219054"]}, {"Citation": "Khawaja I., Spurling B.C., Singh S. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. REM Sleep Behavior Disorder.", "ArticleIdList": ["30480972"]}, {"Citation": "Lerner A.B., Case J.D., Takahashi Y., Lee T.H., Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc. 1958;80:2587. doi: 10.1021/ja01543a060.", "ArticleIdList": ["10.1021/ja01543a060"]}, {"Citation": "Slominski A., Wortsman J., Tobin D.J. The cutaneous serotoninergic/melatoninergic system: Securing a place under the sun. FASEB J. 2005;19:176\u2013194. doi: 10.1096/fj.04-2079rev.", "ArticleIdList": ["10.1096/fj.04-2079rev", "15677341"]}, {"Citation": "Kholghi G., Eskandari M., Shokouhi Qare Saadlou M.S., Zarrindast M.R., Vaseghi S. Night shift hormone: How does melatonin affect depression? Physiol. Behav. 2022;252:113835. doi: 10.1016/j.physbeh.2022.113835.", "ArticleIdList": ["10.1016/j.physbeh.2022.113835", "35504318"]}, {"Citation": "Touitou Y. Melatonin: Hormone and medication. C. R. Seances Soc. Biol. Fil. 1998;192:643\u2013657.", "ArticleIdList": ["9842469"]}, {"Citation": "Tordjman S., Chokron S., Delorme R., Charrier A., Bellissant E., Jaafari N., Fougerou C. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr. Neuropharmacol. 2017;15:434\u2013443. doi: 10.2174/1570159X14666161228122115.", "ArticleIdList": ["10.2174/1570159X14666161228122115", "PMC5405617", "28503116"]}, {"Citation": "Brzezinski A. Melatonin in humans. N. Engl. J. Med. 1997;336:186\u2013195. doi: 10.1056/NEJM199701163360306.", "ArticleIdList": ["10.1056/NEJM199701163360306", "8988899"]}, {"Citation": "Zisapel N. Sleep and sleep disturbances: Biological basis and clinical implications. Cell. Mol. Life Sci. 2007;64:1174\u20131186. doi: 10.1007/s00018-007-6529-9.", "ArticleIdList": ["10.1007/s00018-007-6529-9", "17364142"]}, {"Citation": "Liu C., Weaver D.R., Jin X., Shearman L.P., Pieschl R.L., Gribkoff V.K., Reppert S.M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91\u2013102. doi: 10.1016/S0896-6273(00)80350-5.", "ArticleIdList": ["10.1016/S0896-6273(00)80350-5", "9247266"]}, {"Citation": "Gorfine T., Assaf Y., Goshen-Gottstein Y., Yeshurun Y., Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006;31:410\u2013418. doi: 10.1016/j.neuroimage.2005.11.024.", "ArticleIdList": ["10.1016/j.neuroimage.2005.11.024", "16427787"]}, {"Citation": "Gorfine T., Zisapel N. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum. Brain Mapp. 2009;30:541\u2013552. doi: 10.1002/hbm.20525.", "ArticleIdList": ["10.1002/hbm.20525", "PMC6871121", "18095278"]}, {"Citation": "Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol. 2018;175:3190\u20133199. doi: 10.1111/bph.14116.", "ArticleIdList": ["10.1111/bph.14116", "PMC6057895", "29318587"]}, {"Citation": "Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010;62:343\u2013380. doi: 10.1124/pr.110.002832.", "ArticleIdList": ["10.1124/pr.110.002832", "PMC2964901", "20605968"]}, {"Citation": "Omeiza N.A., Abdulrahim H.A., Alagbonsi A.I., Ezurike P.U., Soluoku T.K., Isiabor H., Alli-Oluwafuyi A.A. Melatonin salvages lead-induced neuro-cognitive shutdown, anxiety, and depressive-like symptoms via oxido-inflammatory and cholinergic mechanisms. Brain Behav. 2021;11:e2227. doi: 10.1002/brb3.2227.", "ArticleIdList": ["10.1002/brb3.2227", "PMC8413791", "34087957"]}, {"Citation": "Klosen P., Lapmanee S., Schuster C., Guardiola B., Hicks D., Pevet P., Felder-Schmittbuhl M.P. MT1 and MT2 melatonin receptors are expressed in nonoverlapping neuronal populations. J. Pineal Res. 2019;67:e12575. doi: 10.1111/jpi.12575.", "ArticleIdList": ["10.1111/jpi.12575", "30937953"]}, {"Citation": "Gobbi G., Comai S. Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep. Front. Endocrinol. 2019;10:87. doi: 10.3389/fendo.2019.00087.", "ArticleIdList": ["10.3389/fendo.2019.00087", "PMC6407453", "30881340"]}, {"Citation": "Zisapel N. Circadian rhythm sleep disorders: Pathophysiology and potential approaches to management. CNS Drugs. 2001;15:311\u2013328. doi: 10.2165/00023210-200115040-00005.", "ArticleIdList": ["10.2165/00023210-200115040-00005", "11463135"]}, {"Citation": "Karasek M., Winczyk K. Melatonin in humans. J. Physiol. Pharmacol. 2006;57((Suppl. 5)):19\u201339.", "ArticleIdList": ["17218758"]}, {"Citation": "Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed. Pharmacother. 2006;60:97\u2013108. doi: 10.1016/j.biopha.2006.01.002.", "ArticleIdList": ["10.1016/j.biopha.2006.01.002", "16527442"]}, {"Citation": "Jockers R., Maurice P., Boutin J.A., Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: What\u2019s new? Br. J. Pharmacol. 2008;154:1182\u20131195. doi: 10.1038/bjp.2008.184.", "ArticleIdList": ["10.1038/bjp.2008.184", "PMC2483381", "18493248"]}, {"Citation": "Khan M.Z., He L. Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology. 2017;234:1181\u20131207. doi: 10.1007/s00213-017-4586-9.", "ArticleIdList": ["10.1007/s00213-017-4586-9", "28289782"]}, {"Citation": "Reppert S.M., Weaver D.R., Ebisawa T., Mahle C.D., Kolakowski L.F., Jr. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996;386:219\u2013224. doi: 10.1016/0014-5793(96)00437-1.", "ArticleIdList": ["10.1016/0014-5793(96)00437-1", "8647286"]}, {"Citation": "Macintyre D.J., McGhee K.A., Maclean A.W., Afzal M., Briffa K., Henry B., Thomson P.A., Muir W.J., Blackwood D.H. Association of GPR50, an X-linked orphan G protein-coupled receptor, and affective disorder in an independent sample of the Scottish population. Neurosci. Lett. 2010;475:169\u2013173. doi: 10.1016/j.neulet.2010.03.072.", "ArticleIdList": ["10.1016/j.neulet.2010.03.072", "20371266"]}, {"Citation": "Thomson P.A., Wray N.R., Thomson A.M., Dunbar D.R., Grassie M.A., Condie A., Walker M.T., Smith D.J., Pulford D.J., Muir W., et al. Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry. 2005;10:470\u2013478. doi: 10.1038/sj.mp.4001593.", "ArticleIdList": ["10.1038/sj.mp.4001593", "15452587"]}, {"Citation": "Levoye A., Dam J., Ayoub M.A., Guillaume J.L., Couturier C., Delagrange P., Jockers R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006;25:3012\u20133023. doi: 10.1038/sj.emboj.7601193.", "ArticleIdList": ["10.1038/sj.emboj.7601193", "PMC1500982", "16778767"]}, {"Citation": "Adi N., Mash D.C., Ali Y., Singer C., Shehadeh L., Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson\u2019s disease. Med. Sci. Monit. 2010;16:BR61\u2013BR67.", "ArticleIdList": ["20110911"]}, {"Citation": "Srinivasan V., Cardinali D.P., Srinivasan U.S., Kaur C., Brown G.M., Spence D.W., Hardeland R., Pandi-Perumal S.R. Therapeutic potential of melatonin and its analogs in Parkinson\u2019s disease: Focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 2011;4:297\u2013317. doi: 10.1177/1756285611406166.", "ArticleIdList": ["10.1177/1756285611406166", "PMC3187674", "22010042"]}, {"Citation": "Kato K., Hirai K., Nishiyama K., Uchikawa O., Fukatsu K., Ohkawa S., Kawamata Y., Hinuma S., Miyamoto M. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301\u2013310. doi: 10.1016/j.neuropharm.2004.09.007.", "ArticleIdList": ["10.1016/j.neuropharm.2004.09.007", "15695169"]}, {"Citation": "Srinivasan V., Pandi-Perumal S., Cardinali D., Poeggeler B., Hardeland R. Melatonin in Alzheimer\u2019s disease and other neurodegenerative disorders. Behav. Brain Funct. 2006;2:15. doi: 10.1186/1744-9081-2-15.", "ArticleIdList": ["10.1186/1744-9081-2-15", "PMC1483829", "16674804"]}, {"Citation": "Leston J., Harthe C., Brun J., Mottolese C., Mertens P., Sindou M., Claustrat B. Melatonin is released in the third ventricle in humans. A study in movement disorders. Neurosci. Lett. 2010;469:294\u2013297. doi: 10.1016/j.neulet.2009.12.008.", "ArticleIdList": ["10.1016/j.neulet.2009.12.008", "20004701"]}, {"Citation": "Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in Parkinson\u2019s disease. J. Neural Transm. Park. Dis. Dement. Sect. 1991;3:41\u201347. doi: 10.1007/BF02251135.", "ArticleIdList": ["10.1007/BF02251135", "2064730"]}, {"Citation": "Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: Evidence for phase-shifting properties of l-dopa. J. Neural Transm. Park. Dis. Dement. Sect. 1993;5:227\u2013234. doi: 10.1007/BF02257677.", "ArticleIdList": ["10.1007/BF02257677", "8369102"]}, {"Citation": "Willis G.L. Parkinson\u2019s disease as a neuroendocrine disorder of circadian function: Dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci. 2008;19:245\u2013316. doi: 10.1515/REVNEURO.2008.19.4-5.245.", "ArticleIdList": ["10.1515/REVNEURO.2008.19.4-5.245", "19145986"]}, {"Citation": "Videnovic A., Noble C., Reid K.J., Peng J., Turek F.W., Marconi A., Rademaker A.W., Simuni T., Zadikoff C., Zee P.C. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71:463\u2013469. doi: 10.1001/jamaneurol.2013.6239.", "ArticleIdList": ["10.1001/jamaneurol.2013.6239", "PMC4078989", "24566763"]}, {"Citation": "Breen D.P., Nombela C., Vuono R., Jones P.S., Fisher K., Burn D.J., Brooks D.J., Reddy A.B., Rowe J.B., Barker R.A. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson\u2019s disease. Mov. Disord. 2016;31:1062\u20131066. doi: 10.1002/mds.26592.", "ArticleIdList": ["10.1002/mds.26592", "PMC5025727", "26971528"]}, {"Citation": "Uysal H.A., Tiftikcioglu B.I., Ocek L., Zorlu Y. Serum Levels of Melatonin and Sleep Evaluation Scales in the Diagnosis of Sleep Disorders in Patients with Idiopathic Parkinson\u2019s Disease. Noro Psikiyatr. Ars. 2019;56:264\u2013268. doi: 10.5152/npa.2017.19367.", "ArticleIdList": ["10.5152/npa.2017.19367", "PMC6927091", "31903034"]}, {"Citation": "Al-Ghoul W.M., Herman M.D., Dubocovich M.L. Melatonin receptor subtype expression in human cerebellum. Neuroreport. 1998;9:4063\u20134068. doi: 10.1097/00001756-199812210-00011.", "ArticleIdList": ["10.1097/00001756-199812210-00011", "9926848"]}, {"Citation": "Savaskan E., Olivieri G., Meier F., Brydon L., Jockers R., Ravid R., Wirz-Justice A., Muller-Spahn F. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer\u2019s disease patients. J. Pineal Res. 2002;32:59\u201362. doi: 10.1034/j.1600-079x.2002.00841.x.", "ArticleIdList": ["10.1034/j.1600-079x.2002.00841.x", "11841602"]}, {"Citation": "Uz T., Arslan A.D., Kurtuncu M., Imbesi M., Akhisaroglu M., Dwivedi Y., Pandey G.N., Manev H. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res. Mol. Brain Res. 2005;136:45\u201353. doi: 10.1016/j.molbrainres.2005.01.002.", "ArticleIdList": ["10.1016/j.molbrainres.2005.01.002", "15893586"]}, {"Citation": "Escames G., Acuna Castroviejo D., Vives F. Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport. 1996;7:597\u2013600. doi: 10.1097/00001756-199601310-00053.", "ArticleIdList": ["10.1097/00001756-199601310-00053", "8730838"]}, {"Citation": "Hu X., Li J., Wang X., Liu H., Wang T., Lin Z., Xiong N. Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson\u2019s Disease. Antioxidants. 2023;12:396. doi: 10.3390/antiox12020396.", "ArticleIdList": ["10.3390/antiox12020396", "PMC9952101", "36829955"]}, {"Citation": "Van Someren E. Circadian and sleep disturbances in the elderly. Exp. Gerontol. 2000;35:1229\u20131237. doi: 10.1016/S0531-5565(00)00191-1.", "ArticleIdList": ["10.1016/S0531-5565(00)00191-1", "11113604"]}, {"Citation": "Lin L., Meng T., Liu T., Zheng Z. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson\u2019s disease. Life Sci. 2013;92:311\u2013316. doi: 10.1016/j.lfs.2013.01.007.", "ArticleIdList": ["10.1016/j.lfs.2013.01.007", "23333823"]}, {"Citation": "Li L., Zhao Z., Ma J., Zheng J., Huang S., Hu S., Gu Q., Chen S. Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson\u2019s Disease: A Cross-Sectional Study. Front. Neurosci. 2020;14:505. doi: 10.3389/fnins.2020.00505.", "ArticleIdList": ["10.3389/fnins.2020.00505", "PMC7248560", "32508583"]}, {"Citation": "Catala M.D., Canete-Nicolas C., Iradi A., Tarazona P.J., Tormos J.M., Pascual-Leone A. Melatonin levels in Parkinson\u2019s disease: Drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. 1997;32:553\u2013558. doi: 10.1016/S0531-5565(96)00173-8.", "ArticleIdList": ["10.1016/S0531-5565(96)00173-8", "9315456"]}, {"Citation": "Korshunov K.S., Blakemore L.J., Trombley P.Q. Dopamine: A Modulator of Circadian Rhythms in the Central Nervous System. Front. Cell. Neurosci. 2017;11:91. doi: 10.3389/fncel.2017.00091.", "ArticleIdList": ["10.3389/fncel.2017.00091", "PMC5376559", "28420965"]}, {"Citation": "Mendoza J., Challet E. Circadian insights into dopamine mechanisms. Neuroscience. 2014;282:230\u2013242. doi: 10.1016/j.neuroscience.2014.07.081.", "ArticleIdList": ["10.1016/j.neuroscience.2014.07.081", "25281877"]}, {"Citation": "Ma H., Yan J., Sun W., Jiang M., Zhang Y. Melatonin Treatment for Sleep Disorders in Parkinson\u2019s Disease: A Meta-Analysis and Systematic Review. Front. Aging Neurosci. 2022;14:784314. doi: 10.3389/fnagi.2022.784314.", "ArticleIdList": ["10.3389/fnagi.2022.784314", "PMC8855052", "35185525"]}, {"Citation": "Fatemeh G., Sajjad M., Niloufar R., Neda S., Leila S., Khadijeh M. Effect of melatonin supplementation on sleep quality: A systematic review and meta-analysis of randomized controlled trials. J. Neurol. 2022;269:205\u2013216. doi: 10.1007/s00415-020-10381-w.", "ArticleIdList": ["10.1007/s00415-020-10381-w", "33417003"]}, {"Citation": "Sun X., Ran D., Zhao X., Huang Y., Long S., Liang F., Guo W., Nucifora F.C., Jr., Gu H., Lu X., et al. Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a Drosophila model of Parkinson\u2019s disease. Mol. Med. Rep. 2016;13:3936\u20133944. doi: 10.3892/mmr.2016.4991.", "ArticleIdList": ["10.3892/mmr.2016.4991", "26985725"]}, {"Citation": "Lyashenko E.A., Levin O.S., Poluektov M.G. Melatonin in correction of REM-sleep behavior disorders in Parkinson\u2019s disease. Zhurnal Nevrol. I Psikhiatrii Im. SS Korsakova. 2015;115:40\u201343. doi: 10.17116/jnevro20151156240-43.", "ArticleIdList": ["10.17116/jnevro20151156240-43", "28635783"]}, {"Citation": "Boeve B.F., Silber M.H., Ferman T.J. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med. 2003;4:281\u2013284. doi: 10.1016/S1389-9457(03)00072-8.", "ArticleIdList": ["10.1016/S1389-9457(03)00072-8", "14592300"]}, {"Citation": "Anderson K.N., Shneerson J.M. Drug treatment of REM sleep behavior disorder: The use of drug therapies other than clonazepam. J. Clin. Sleep Med. 2009;5:235\u2013239. doi: 10.5664/jcsm.27492.", "ArticleIdList": ["10.5664/jcsm.27492", "PMC2699168", "19960644"]}, {"Citation": "Takeuchi N., Uchimura N., Hashizume Y., Mukai M., Etoh Y., Yamamoto K., Kotorii T., Ohshima H., Ohshima M., Maeda H. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin. Neurosci. 2001;55:267\u2013269. doi: 10.1046/j.1440-1819.2001.00854.x.", "ArticleIdList": ["10.1046/j.1440-1819.2001.00854.x", "11422870"]}, {"Citation": "Kunz D., Bes F. Melatonin effects in a patient with severe REM sleep behavior disorder: Case report and theoretical considerations. Neuropsychobiology. 1997;36:211\u2013214. doi: 10.1159/000119383.", "ArticleIdList": ["10.1159/000119383", "9396020"]}, {"Citation": "Rajaratnam S.M., Polymeropoulos M.H., Fisher D.M., Roth T., Scott C., Birznieks G., Klerman E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet. 2009;373:482\u2013491. doi: 10.1016/S0140-6736(08)61812-7.", "ArticleIdList": ["10.1016/S0140-6736(08)61812-7", "19054552"]}, {"Citation": "Kunz D., Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J. Sleep. Res. 2010;19:591\u2013596. doi: 10.1111/j.1365-2869.2010.00848.x.", "ArticleIdList": ["10.1111/j.1365-2869.2010.00848.x", "20561180"]}, {"Citation": "Gilat M., Coeytaux Jackson A., Marshall N.S., Hammond D., Mullins A.E., Hall J.M., Fang B.A.M., Yee B.J., Wong K.K.H., Grunstein R.R., et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson\u2019s disease: A randomised controlled trial. Mov. Disord. 2020;35:344\u2013349. doi: 10.1002/mds.27886.", "ArticleIdList": ["10.1002/mds.27886", "PMC7027846", "31674060"]}, {"Citation": "Ahn J.H., Kim M., Park S., Jang W., Park J., Oh E., Cho J.W., Kim J.S., Youn J. Prolonged-release melatonin in Parkinson\u2019s disease patients with a poor sleep quality: A randomized trial. Parkinsonism Relat. Disord. 2020;75:50\u201354. doi: 10.1016/j.parkreldis.2020.03.029.", "ArticleIdList": ["10.1016/j.parkreldis.2020.03.029", "32480307"]}, {"Citation": "Byun J.I., Shin Y.Y., Seong Y.A., Yoon S.M., Hwang K.J., Jung Y.J., Cha K.S., Jung K.Y., Shin W.C. Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder. Sleep Breath. 2023;27:309\u2013318. doi: 10.1007/s11325-022-02572-8.", "ArticleIdList": ["10.1007/s11325-022-02572-8", "35141811"]}, {"Citation": "McGrane I.R., Leung J.G., St Louis E.K., Boeve B.F. Melatonin therapy for REM sleep behavior disorder: A critical review of evidence. Sleep Med. 2015;16:19\u201326. doi: 10.1016/j.sleep.2014.09.011.", "ArticleIdList": ["10.1016/j.sleep.2014.09.011", "PMC4306603", "25454845"]}, {"Citation": "Coloma F.M., Niles L.P. Melatonin enhancement of [3H]-\u03b3-aminobutyric acid and [3H]muscimol binding in rat brain. Biochem. Pharmacol. 1988;37:1271\u20131274. doi: 10.1016/0006-2952(88)90781-2.", "ArticleIdList": ["10.1016/0006-2952(88)90781-2", "2833276"]}, {"Citation": "Wu F.S., Yang Y.C., Tsai J.J. Melatonin potentiates the GABA(A) receptor-mediated current in cultured chick spinal cord neurons. Neurosci. Lett. 1999;260:177\u2013180. doi: 10.1016/S0304-3940(98)00983-5.", "ArticleIdList": ["10.1016/S0304-3940(98)00983-5", "10076896"]}, {"Citation": "McCarter S.J., Boswell C.L., St Louis E.K., Dueffert L.G., Slocumb N., Boeve B.F., Silber M.H., Olson E.J., Tippmann-Peikert M. Treatment outcomes in REM sleep behavior disorder. Sleep. Med. 2013;14:237\u2013242. doi: 10.1016/j.sleep.2012.09.018.", "ArticleIdList": ["10.1016/j.sleep.2012.09.018", "PMC3617579", "23352028"]}, {"Citation": "Lin C.-M., Chiu H.-Y., Guilleminault C. Melatonin and REM behavior disorder. J. Sleep. Disord. Ther. 2013;2:1\u20139. doi: 10.4172/2167-0277.1000118.", "ArticleIdList": ["10.4172/2167-0277.1000118"]}, {"Citation": "Limousin N., Dehais C., Gout O., Heran F., Oudiette D., Arnulf I. A brainstem inflammatory lesion causing REM sleep behavior disorder and sleepwalking (parasomnia overlap disorder) Sleep Med. 2009;10:1059\u20131062. doi: 10.1016/j.sleep.2008.12.006.", "ArticleIdList": ["10.1016/j.sleep.2008.12.006", "19345142"]}, {"Citation": "Stokholm M.G., Iranzo A., Ostergaard K., Serradell M., Otto M., Svendsen K.B., Garrido A., Vilas D., Borghammer P., Santamaria J., et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. Lancet Neurol. 2017;16:789\u2013796. doi: 10.1016/S1474-4422(17)30173-4.", "ArticleIdList": ["10.1016/S1474-4422(17)30173-4", "28684245"]}, {"Citation": "Hasikova L., Zavada J., Serranova T., Kotackova L., Kozlik P., Kalikova K., Trnka J., Zogala D., Sonka K., Ruzicka E., et al. Patients with REM sleep behavior disorder have higher serum levels of allantoin. Park. Relat. Disord. 2021;90:38\u201343. doi: 10.1016/j.parkreldis.2021.07.031.", "ArticleIdList": ["10.1016/j.parkreldis.2021.07.031", "34352609"]}, {"Citation": "Wang X., Wang Z., Cao J., Dong Y., Chen Y. Melatonin ameliorates anxiety-like behaviors induced by sleep deprivation in mice: Role of oxidative stress, neuroinflammation, autophagy and apoptosis. Brain Res. Bull. 2021;174:161\u2013172. doi: 10.1016/j.brainresbull.2021.06.010.", "ArticleIdList": ["10.1016/j.brainresbull.2021.06.010", "34144202"]}, {"Citation": "Morvaridzadeh M., Sadeghi E., Agah S., Nachvak S.M., Fazelian S., Moradi F., Persad E., Heshmati J. Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis. Pharmacol. Res. 2020;161:105210. doi: 10.1016/j.phrs.2020.105210.", "ArticleIdList": ["10.1016/j.phrs.2020.105210", "33007423"]}, {"Citation": "Tamtaji O.R., Reiter R.J., Alipoor R., Dadgostar E., Kouchaki E., Asemi Z. Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. Cell. Mol. Neurobiol. 2020;40:15\u201323. doi: 10.1007/s10571-019-00720-5.", "ArticleIdList": ["10.1007/s10571-019-00720-5", "31388798"]}, {"Citation": "Paul R., Phukan B.C., Justin Thenmozhi A., Manivasagam T., Bhattacharya P., Borah A. Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson\u2019s disease. Life Sci. 2018;192:238\u2013245. doi: 10.1016/j.lfs.2017.11.016.", "ArticleIdList": ["10.1016/j.lfs.2017.11.016", "29138117"]}, {"Citation": "Ringman J.M., Simmons J.H. Treatment of REM sleep behavior disorder with donepezil: A report of three cases. Neurology. 2000;55:870\u2013871. doi: 10.1212/WNL.55.6.870.", "ArticleIdList": ["10.1212/WNL.55.6.870", "10994012"]}, {"Citation": "de Almeida-Paula L.D., Costa-Lotufo L.V., Silva Ferreira Z., Monteiro A.E., Isoldi M.C., Godinho R.O., Markus R.P. Melatonin modulates rat myotube-acetylcholine receptors by inhibiting calmodulin. Eur. J. Pharmacol. 2005;525:24\u201331. doi: 10.1016/j.ejphar.2005.09.056.", "ArticleIdList": ["10.1016/j.ejphar.2005.09.056", "16297382"]}, {"Citation": "Markus R.P., Silva C.L., Franco D.G., Barbosa E.M., Jr., Ferreira Z.S. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol. Ther. 2010;126:251\u2013262. doi: 10.1016/j.pharmthera.2010.02.009.", "ArticleIdList": ["10.1016/j.pharmthera.2010.02.009", "20398699"]}, {"Citation": "Benitez-King G. Melatonin as a cytoskeletal modulator: Implications for cell physiology and disease. J. Pineal Res. 2006;40:1\u20139. doi: 10.1111/j.1600-079X.2005.00282.x.", "ArticleIdList": ["10.1111/j.1600-079X.2005.00282.x", "16313492"]}, {"Citation": "Zhdanova I.V., Wurtman R.J., Morabito C., Piotrovska V.R., Lynch H.J. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19:423\u2013431. doi: 10.1093/sleep/19.5.423.", "ArticleIdList": ["10.1093/sleep/19.5.423", "8843534"]}, {"Citation": "Attenburrow M.E., Cowen P.J., Sharpley A.L. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology. 1996;126:179\u2013181. doi: 10.1007/BF02246354.", "ArticleIdList": ["10.1007/BF02246354", "8856838"]}, {"Citation": "Kunz D., Mahlberg R., Muller C., Tilmann A., Bes F. Melatonin in patients with reduced REM sleep duration: Two randomized controlled trials. J. Clin. Endocrinol. Metab. 2004;89:128\u2013134. doi: 10.1210/jc.2002-021057.", "ArticleIdList": ["10.1210/jc.2002-021057", "14715839"]}, {"Citation": "Kunz D., Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: An open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov. Disord. 1999;14:507\u2013511. doi: 10.1002/1531-8257(199905)14:3<507::AID-MDS1021>3.0.CO;2-8.", "ArticleIdList": ["10.1002/1531-8257(199905)14:3<507::AID-MDS1021>3.0.CO;2-8", "10348479"]}, {"Citation": "Bonakis A., Economou N.T., Papageorgiou S.G., Vagiakis E., Nanas S., Paparrigopoulos T. Agomelatine may improve REM sleep behavior disorder symptoms. J. Clin. Psychopharmacol. 2012;32:732\u2013734. doi: 10.1097/JCP.0b013e31826866f8.", "ArticleIdList": ["10.1097/JCP.0b013e31826866f8", "22926620"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "5", "Day": "8"}, {"Year": "2023", "Month": "6", "Day": "1"}, {"Year": "2023", "Month": "6", "Day": "3"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "1", "Minute": "7"}, {"Year": "2023", "Month": "6", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["37371392", "PMC10296587", "10.3390/brainsci13060914", "brainsci13060914"]}}], "PubmedBookArticle": []}